{'fraction_non_alphanumeric': 0.06223175965665236, 'fraction_numerical': 0.0890557939914163, 'mean_word_length': 5.058441558441558, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of SK&F 94482 (BMY‐25368) on 24‐hour intragastric acidity and plasma gastrin concentration in healthy subjects

In a double‐blind, placebo‐controlled study of SK&F 94482 (BMY‐25368) (400‐mg, post‐evening meal, for 7 days in 11 healthy subjects), there was a significant 75% decrease in median integrated 24‐h intragastric acidity during dosing with the drug (218 mmol h/L) compared with placebo (883 mmol h/L; P= 0.003). The single daily dose of 400 mg SK&F 94482 decreased median hourly intragastric acidity until the time of the next dose 24 h later. There was also a sustained and significant 80% rise in median 24‐h integrated plasma‐gastrin concentration during dosing with SK&F 94482 (364 pmol h/L) when compared with placebo (202 pmol h/L; P= 0.003). The study demonstrates a significant inverse correlation between 24‐h integrated intragastric acidity and 24‐h plasma gastrin concentration (rs=−0.484; P < 0.001).